You are here

Our science / Clinical Trials / Find a Trial / NCT00219622

A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease

Back to Search Print Save as PDF Bookmark Trial

NCT00219622

Last updated on March 14, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Phoenix, Arizona, 85006 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Chronic Obstructive Pulmonary Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Moderate-severe COPD (GOLD 2003 definition)

- Smoking history of at least 10 pack-years

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Any significant co-morbid disease, particularly cardiovascular

- Use of any maintenance therapy except short acting bronchodilators

NCT00219622
Pfizer
Completed
A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Chronic Obstructive Pulmonary Disease
Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.
NCT00430300
All Genders
40+
Years
Multiple Sites
Chronic Obstructive Pulmonary Disease
Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD
NCT00263874
All Genders
40+
Years
Multiple Sites
Chronic Obstructive Pulmonary Disease
A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers
NCT01364519
All Genders
18+
Years
Multiple Sites
Chronic Obstructive Pulmonary Disease
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination
NCT01321463
All Genders
40+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now